Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-716) Trial for the Treatment of Resected Stage IIB or IIC Melanoma at ASCO 2022
- The P-III (KEYNOTE-716) trial evaluated Keytruda vs PBO in 976 adult and pediatric patients aged ≥12yrs. with resected stage IIB or IIC melanoma
- The results showed a significant clinical improvement in DMFS at a median follow-up of 27.4mos., m- DMFS was not reached. Additionally at the median 27.4mos. follow-up, the therapy showed a reduction in the risk of recurrence, 81.2% vs 72.8% were recurrence-free @2yrs
- The safety profile was consistent with prior reported studies & no new safety signals were observed at the time of DMFS analysis. TRAEs grade ≥3 (17% vs 5%), immune-mediated events and infusion reactions (38% vs 9%). The prespecified exploratory analysis showed that HRQoL was similar b/w Keytruda & PBO
Ref: Businesswire| Image: Merck
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.